NIKKEI 225
38,102.44 -712.12 (-1.83%) HANG SENG
17,936.12 -5.66 (-0.03%) CRUDE OIL
79.50 +1.05 (+1.34%) GOLD FUTURES
2,329.50 -19.60 (-0.83%) DOW
38,670.48 +81.32 (+0.21%) Bitcoin GBP
51,690.88 -766.61 (-1.46%)
Stereotaxis Inc (RJR1.F)
| Previous close | 1.7400 |
| Open | 1.7000 |
| Bid | 1.7100 x N/A |
| Ask | 1.7600 x N/A |
| Day's range | 1.7000 - 1.7300 |
| 52-week range | 1.2500 - 2.9800 |
| Volume | |
| Avg. volume | 41 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswirePenn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the fore
ZacksStereotaxis (STXS) Gets CE Recertification for Approved Products
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.
ZacksStereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.
